Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04652882 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

StatusActive, Not Recruiting
PhasePhase 3
Started2020-12-09
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 27, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 2026 → Sep 2026
See other at-risk trials from Vanda Pharmaceuticals

Amendment history

2026-07-24
notable
Study Status, Contacts/Locations v9
Enrollment closed, study ongoing
Primary completion pushed: 2026-06 → 2026-09
Completion pushed: 2026-06 → 2026-09
Study sitesdetails revised at 17 of 17 sites
2025-11-24
minor
Study Identification, Study Status, Oversight, Contacts/Locations v8
Primary completion date2025-12→2026-06
Completion date2025-12→2026-06
Study sites21→17
Study titlerevised
Evaluating the Effects of Tasimelteon Vsvs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
2024-11-14
minor
Study Identification, Study Status, Oversight, Study Design, Eligibility, Contacts/Locations v7
Primary completion date2024-12→2025-12
Enrollment target300→70
Study sites18→21
Eligibility criteria+22 characters
[...] are breastfeeding. A positive test for substances of abuse. Current tobacco user.
Study titlerevised
Evaluating the Effects of Tasimelteon vsVs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
2024-04-01
minor
Study Status, Eligibility, Contacts/Locations v6
Primary completion date2022-12→2024-12
Completion date2023-12→2025-12
Study sites15→18
Eligibility criteria+71 characters
[...] ss Index (BMI) of ≥ 18 and ≤ 35 kg/m^2. Exclusion Criteria: HistoryExacerbation of an existing psychiatric disorderscondition withinthat 12requires change in treatment or intervention in the past 3 months. Major surgery, trauma, illness, general anesthesia, [...]
2022-01-12
minor
Study Status, Eligibility, Contacts/Locations v5
Eligibility criteria-119 characters
Inclusion Criteria: Ability and acceptance to provide written informed consent of the participant or legal guardian. Participants ≥ 16 and < 18 years of age will also need to provide written assent. A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD). Men or women between 1618 - 75 years, inclusive. Body Mass Index (BMI) of ≥ 18 and ≤ [...]
Study sitesdetails revised at 6 of 15 sites
Show 4 earlier versions
2021-10-15
minor
Study Status, Contacts/Locations v4
Primary completion date2021-12→2022-12
Completion date2022-12→2023-12
Study sites16→15
2021-06-11
minor
Study Status, Eligibility, Contacts/Locations v3
Study sites11→16
Eligibility criteriarevised
[...] leep-Wake Phase Disorder (DSWPD). Men or women between 16 - 6575 years, inclusive. Body Mass Index (BMI) of ≥ 18 and ≤ 3035 kg/m^2. Exclusion Criteria: History of psychiatric disorder [...]
2021-03-02
minor
Study Status, Eligibility, Contacts/Locations v2
Study sites9→11
Eligibility criteria+119 characters
Inclusion Criteria: Ability and acceptance to provide written informed consent of the participant or legal guardian. Participants ≥ 16 and < 18 years of age will also need to provide written assent. A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD). Men or women between 1816 - 65 years, inclusive. Body Mass Index (BMI) of ≥ 18 and ≤ [...]
2021-01-14
minor
Study Status, Eligibility, Contacts/Locations v1
Start dateestimated 2020-12→confirmed 2020-12-09
Study sites8→9
Eligibility criteria-24 characters
[...] Criteria: History of psychiatric disorders within 12 months (other than depression). Major surgery, trauma, illness, general anesthesia, or imm [...]
2020-12-02
minor
Original filing
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
Trial Details
NCT Number NCT04652882
Lead Sponsor Vanda Pharmaceuticals
Conditions Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
Enrollment 70 participants
Start Date 2020-12-09
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-27